Rutin administration attenuates myocardial dysfunction in diabetic rats by unknown
Guimaraes et al. Cardiovasc Diabetol  (2015) 14:90 
DOI 10.1186/s12933-015-0255-7
ORIGINAL INVESTIGATION
Rutin administration attenuates 
myocardial dysfunction in diabetic rats
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Abstract 
Background: Oxidative stress plays a major role in diabetic cardiomyopathy pathogenesis. Anti-oxidant therapy has 
been investigated in preventing or treating several diabetic complications. However, anti-oxidant action on diabetic-
induced cardiac remodeling is not completely clear. This study evaluated the effects of rutin, a flavonoid, on cardiac 
and myocardial function in diabetic rats.
Methods: Wistar rats were assigned into control (C, n = 14); control-rutin (C-R, n = 14); diabetes mellitus (DM, 
n = 16); and DM-rutin (DM-R, n = 16) groups. Seven days after inducing diabetes (streptozotocin, 60 mg/kg, i.p.), rutin 
was injected intraperitoneally once a week (50 mg/kg) for 7 weeks. Echocardiogram was performed and myocardial 
function assessed in left ventricular (LV) papillary muscles. Serum insulin concentration was measured by ELISA. Statis-
tics: One-way ANOVA and Tukey’s post hoc test.
Results: Glycemia was higher in DM than DM-R and C and in DM-R than C-R. Insulin concentration was lower in dia-
betic groups than controls (C 2.45 ± 0.67; C-R 2.09 ± 0.52; DM 0.59 ± 0.18; DM-R 0.82 ± 0.21 ng/mL). Echocardiogram 
showed no differences between C-R and C. DM had increased LV systolic diameter compared to C, and increased 
left atrium diameter/body weight (BW) ratio and LV mass/BW ratio compared to C and DM-R. Septal wall thickness, 
LV diastolic diameter/BW ratio, and relative wall thickness were lower in DM-R than DM. Fractional shortening and 
posterior wall shortening velocity were lower in DM than C and DM-R. In papillary muscle preparation, DM and DM-R 
presented higher time to peak tension and time from peak tension to 50% relaxation than controls; time to peak 
tension was lower in DM-R than DM. Under 0.625 and 1.25 mM extracellular calcium concentrations, DM had higher 
developed tension than C.
Conclusion: Rutin attenuates cardiac remodeling and left ventricular and myocardial dysfunction caused by strepto-
zotocin-induced diabetes mellitus.
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Background
Diabetes mellitus is an important public health problem 
because of a high prevalence and increased morbidity 
and mortality. Cardiovascular involvement is frequent in 
diabetes and a major cause of death in diabetic patients 
[1, 2]. Cardiac alterations are caused by both coronary 
atherosclerosis and diabetes-related cardiomyopathy. As 
first reported by Rubler et al. [3], diabetic cardiomyopa-
thy is characterized by left ventricular systolic and dias-
tolic dysfunction in the absence of underlying coronary 
artery disease and/or systemic arterial hypertension [4]. 
Diabetic cardiomyopathy may affect both type 1 and 2 
diabetic patients [5]. The pathophysiology of diabetic 
cardiomyopathy is multifactorial and includes several 
mechanisms such as myocardial fibrosis, myocyte hyper-
trophy, contractile dysfunction, changes in calcium han-
dling and mitochondrial function, impaired nitric oxide 
signaling, and abnormal cardiomyocyte loss by apoptosis 
[5–7]. Despite all these mechanisms, oxidative stress is 
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widely considered a major cause in the pathogenesis of 
diabetic cardiomyopathy [8–10].
In diabetes, oxidative stress can be induced by hyper-
glycemia, hyperlipidemia, and inflammation. Oxida-
tive stress occurs when the production of reactive 
oxygen species exceeds their degradation by anti-oxidant 
defenses [9, 11]. Anti-oxidant therapy has been exten-
sively studied to prevent or treat several diabetic com-
plications [12–14]; however, direct investigations on the 
role of anti-oxidants on diabetic-induced cardiac remod-
eling remain relatively scarce [9].
Flavonoids are natural substances with variable phe-
nolic structures that have been used for their anti-oxi-
dant properties [15]. In diabetic rats, flavonoids reversed 
cardiac dysfunction and structural changes and attenu-
ated oxidative stress and cardiac dysfunction induced by 
ischemia–reperfusion injury [16, 17]. More than 4,000 
varieties of flavonoids have been identified [15, 18]. One 
of the main flavonoids is rutin, which can be extracted 
from many nature sources, including buckwheat, 
oranges, grapes, lemons, limes, peaches, and berries [19]. 
Recently, rutin was shown to attenuate oxidative stress, 
apoptosis, and inflammation in diabetic rat hearts [19]. 
In this study, we evaluated the effects of rutin on cardiac 
and myocardial function in rats with streptozotocin-
induced diabetes.
Methods
Male Wistar rats weighing 300–350  g were purchased 
from the Central Animal House at Botucatu Medi-
cal School, UNESP. All animals were housed in a tem-
perature controlled room 25 ±  2ºC and kept on a 12  h 
light/dark cycle. All experiments and procedures were 
approved by Botucatu Medical School Ethics Commit-
tee, Sao Paulo State University, UNESP, and performed 
in compliance with the ARRIVE guidelines on animal 
research [20].
Diabetes was induced by intraperitoneal injection of 
streptozotocin (STZ, Sigma, St. Louis, MO, USA) at a 
dose of 60  mg/kg body weight, dissolved in 0.1  M cit-
rate buffer, pH 4.5 [21, 22]. Forty-eight hours after STZ 
administration, blood glucose was measured by glucom-
eter (Boehringer Mannheim, Eli Lilly Ltd., São Paulo, 
Brazil). Only STZ-treated rats with glycemia >250 mg/dL 
were considered diabetic and included in the study [23]. 
Rats were randomly assigned into four groups:
1. control group (C, n = 14)—rats treated with vehicle;
2. control-rutin (C-R, n = 14) group—rats treated with 
rutin;
3. diabetes mellitus (DM, n = 16) group—diabetic rats 
treated with vehicle;
4. DM-rutin (DM-R, n  =  16) group—diabetic rats 
treated with rutin.
Seven days after STZ injection, rutin (Sigma, St. Louis, 
MO, USA) was administered once a week at a dose of 
50  mg/kg body weight, for 7  weeks. Rutin was solubi-
lized in 500 μL of propylene glycol; the volume was then 
completed to 500 μL with water and injected intraperi-
toneally. Food and water were supplied ad  libitum. To 
adjust rutin dose, individual rat food (g) and water (mL) 
intake was measured daily. Body weight was measured 
weekly. At the end of experimental period (56 days), rats 
were fasted for 12 h, anesthetized, and decapitated.
Echocardiographic study
Echocardiographic evaluation was performed at the 
end of the study using a commercially available echo-
cardiograph (General Electric Medical Systems, Vivid 
S6, Tirat Carmel, Israel) equipped with a 5–11.5  MHz 
multifrequency probe, as previously described [24–26]. 
Rats were anesthetized by intramuscular injection of a 
ketamine (50  mg/kg) and xylazine (0.5  mg/kg) mixture. 
A two-dimensional parasternal short-axis view of the 
left ventricle (LV) was obtained at the level of the pap-
illary muscles. M-mode tracings were obtained from 
short-axis views of the LV at or just below the tip of the 
mitral-valve leaflets, and at the level of the aortic valve 
and left atrium. M-mode images of the LV were printed 
on a black-and-white thermal printer (Sony UP-890MD) 
at a sweep speed of 100  mm/s. All LV structures were 
manually measured by the same observer (KO) accord-
ing to the leading-edge method of the American Society 
of Echocardiography. Means were obtained from meas-
urements of at least five cardiac cycles on the M-mode 
tracings. The following structural variables were meas-
ured: LV diastolic and systolic diameters (LVDD and 
LVSD, respectively), LV diastolic posterior wall thickness 
(PWT), LV diastolic septal wall thickness (SWT), and left 
atrium diameter (LA). Left ventricular mass (LVM) was 
calculated using the formula [(LVDD + PWT + SWT)3 
−  (LVDD)3]  ×  1.04. LV relative wall thickness (RWT) 
was calculated by the formula 2 × PWT/LVDD. LV func-
tion was assessed by the following parameters: endocar-
dial fractional shortening (FS), posterior wall shortening 
velocity (PWSV), early and late diastolic mitral inflow 
velocities (E and A waves), and E/A ratio [27].
Myocardial functional study
One day after the echocardiographic study, myocardial 
intrinsic contractile function was evaluated in isolated 
LV papillary muscles as previously described [28–30]. 
Rats were anesthetized (pentobarbital sodium, 50 mg/kg, 
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intraperitoneally) and decapitated. Hearts were quickly 
removed and placed in oxygenated Krebs–Henseleit solu-
tion at 28°C. LV anterior or posterior papillary muscle was 
dissected free, mounted between two spring clips, and 
placed vertically in a chamber containing Krebs–Henseleit 
solution at 28°C and oxygenated with a mixture of 95% O2 
and 5% CO2 (pH 7.38). Krebs–Henseleit solution compo-
sition in mM was as follows: 118.5 NaCl, 4.69 KCl, 2.50 
CaCl2, 1.16 MgSO4, 1.18 KH2PO4, 5.50 glucose, and 25.88 
NaHCO3. The spring clips were attached to a Kyowa model 
120T-20B force transducer and a lever system, which 
allowed for muscle length adjustment. Preparations were 
stimulated 12 times/min at a voltage 10% above threshold.
After a 60 min period, during which preparations were 
permitted to shorten while carrying light loads, muscles 
were loaded to isometrically contract and stretched to 
the apices of their length-tension curves. After a 5  min 
period, during which preparations performed isotonic 
contractions, muscles were again placed under isomet-
ric conditions, and the apex of the length-tension curve 
(Lmax) was determined. A 15 min period of stable isomet-
ric contraction was imposed prior to the experimental 
period. One isometric contraction was then recorded for 
later analysis.
The following parameters were measured from isomet-
ric contraction: peak of developed tension (DT, g/mm2), 
time to peak of tension (TPT, ms), time from peak ten-
sion to 50% relaxation (RT1/2), maximum rate of tension 
development (+dT/dt, g/mm2/s), and maximum rate of 
tension decline (−dT/dt, g/mm2/s). Myocardial func-
tion was also evaluated under different extracellular Ca2+ 
concentrations [31, 32].
Papillary muscle cross-sectional area was calculated 
from muscle weight and length by assuming cylindri-
cal uniformity and a specific gravity of 1.0. All force data 
were normalized for muscle cross-sectional area [33].
Anatomical parameters
After dissecting papillary muscle, right and left ventri-
cles were separated and weighed. Lung fragments were 
weighed before and after drying sessions (65°C for 72 h) 
to evaluate wet/dry weight ratio [34, 35].
Biochemical analyses
Glycemia was measured by the enzymatic method using 
glucose oxidase and peroxidase. Serum insulin con-
centration was determined by enzyme immune assay 
kit (EIA kit, Cayman Chemical, USA), using an ELISA 
reader (Biotech Instruments, Inc., USA) [36].
Statistical analysis
Results are expressed as mean  ±  standard deviation. 
Statistical differences between groups were assessed by 
analysis of variance (ANOVA) in a factorial design 2 × 2 
in the one-way model. The Tukey’s post hoc test was 
used to compare individual groups, when the ANOVA 
revealed a significant F statistic. Statistical significance 
was accepted at p  <  0.05. The statistical analyses were 
performed using Systat for Windows version 12.0 (Systat 
Software Inc, San Jose, CA, USA).
Results
None of the rats died during the experimental period. 
Forty-eight hours after streptozotocin administration, 
glycemia was significantly higher in diabetic than con-
trol groups (C 93.1 ± 3.0; C-R 84.9 ± 6.0; DM 414 ± 77; 
DM-R 417 ±  78  mg/dL). At the end of the experiment, 
glycemia was statistically higher in DM than DM-R and 
C and in DM-R than C-R (C 98.9 ± 13.7; C-R 104 ± 11.9; 
DM 397 ±  57.5; DM-R 149 ±  30.3  mg/dL). At the end 
of the study, serum insulin concentration was signifi-
cantly lower in both diabetic groups compared to their 
respective controls (C 2.45 ± 0.67; C-R 2.09 ± 0.52; DM 
0.59 ± 0.18; DM-R 0.82 ± 0.21 ng/mL).
Table  1 shows anatomical parameters. At the end of 
experiment, body weight (BW) was lower in DM and 
DM-R than their respective controls and higher in DM-R 
than DM. LV and right ventricle weight was lower in DM 
and DM-R than controls.
Table  2 shows cardiac structural echocardiographic 
parameters evaluated at the end of the experimental 
period. C-R did not differ from C. Both DM and DM-R 
presented decreased septal wall thickness and relative 
wall thickness, and increased LV diastolic diameter/BW 
ratio than their respective controls. DM had increased 
LV systolic diameter compared to C, and increased 
left atrium diameter/BW ratio, and LV mass/BW ratio 
than both C and DM-R groups. DM-R presented lower 
LV posterior wall thickness, left atrium diameter, and 
LV mass than C-R, and lower septal wall thickness, LV 
Table 1 Anatomical parameters
Data are expressed as mean ± standard deviation or median and percentiles 25 
and 75%. One-way ANOVA in a factorial design 2 × 2 and Tukey’s post hoc test.
C untreated rats, C-R rutin-treated rats, DM untreated diabetic rats, DM-R rutin-
treated diabetic rats, BW body weight, LV left ventricle, RV right ventricle, Wet/dry 
wet-to-dry weight ratio.
* p < 0.05 vs C; #p < 0.05 vs C-R; §p < 0.05 vs DM.
Parameters C (n = 14) C-R (n = 14) DM (n = 16) DM-R 
(n = 16)
BW Initial (g) 365 ± 24 360 ± 24 409 ± 34 370 ± 27
BW Final (g) 444 ± 42 434 ± 58 287 ± 33* 345 ± 62#§
LV weight (g) 0.85 ± 0.09 0.77 ± 0.13 0.58 ± 0.12* 0.68 ± 0.10#
RV weight (g) 0.25 ± 0.04 0.21 ± 0.05* 0.17 ± 0.05* 0.17 ± 0.05#
Wet/dry Lung 4.72 ± 0.76 4.72 ± 0.92 4.84 ± 0.21 4.98 ± 0.55
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diastolic diameter/BW ratio, and relative wall thickness 
than DM. Table 3 shows LV function. C-R did not differ 
from C. DM had reduced fractional shortening and pos-
terior wall shortening velocity than C and DM-R. DM-R 
presented higher A wave and lower E/A ratio than DM.
Table  4 shows basal papillary muscle functional data. 
DM and DM-R presented higher time to peak of tension 
and time from peak tension to 50% relaxation than their 
respective controls. DM-R had a lower time to peak of 
tension than DM. Under 0.625 and 1.25 mM extracellular 
calcium concentrations, DM had higher developed ten-
sion than C (Figure 1).
Discussion
In this study we showed that rutin attenuated cardiac 
structural changes and left ventricular and myocardial 
dysfunction in rats with streptozotocin-induced diabetes 
mellitus.
Because of its toxic effect on pancreatic β-cells in the 
islets of Langerhans, streptozotocin has been widely used 
to induce type 1 diabetes mellitus in rodents [37–39]. 
As previously reported [37], streptozotocin-induced 
diabetes mellitus was characterized by body weight loss 
and increased blood glucose. Despite similar blood glu-
cose levels 48  h after streptozotocin administration, 
rutin-treated rats presented attenuation in increased 
final blood glucose concentration and body weight loss. 
Administration of isoflavones or isolated rutin has been 
shown to exert an antihyperglycemic effect in humans 
with type 2 diabetes mellitus [40] and in experimental 
models such as streptozotocin-induced diabetes [41, 42] 
and obese Zucker rats [43]. At the end of our experiment, 
insulin levels did not statistically differ between DM-R 
and DM groups. A strong relationship was observed 
between flavonoids and glucose metabolism. In cell cul-
ture, flavonoid procyanidins had insulin-like effects on 
insulin sensitive cells [41]. This flavonoid effect could 
explain our result of reduced blood glucose levels despite 
unchanged insulin levels. Furthermore, flavonoids have 
been shown to depress gluconeogenic enzymes and 
inhibit glucose-6-phosphatase in the liver, consequently 
reducing blood glucose release [44].
Echocardiographic evaluation showed diabetic rats 
presenting left cardiac chambers dilation with increased 
LV mass and reduced relative wall thickness, which 
establishes a pattern of LV eccentric hypertrophy. Some 
authors did not observe statistically significant changes 
in echocardiography structures  8  weeks after inducing 
diabetes in rats [45]. It is probable that, in our study, by 
using a greater sample size, we could observe significant 
dilation in left cardiac chambers. Functionally, DM had 
systolic dysfunction characterized by decreased endocar-
dial fractional shortening and posterior wall shortening 
velocity.
Several pathophysiological mechanisms can be involved 
in cardiac injury during diabetes [23, 46]. Impaired myo-
cardial contractility is a major cause of cardiac dilation 
and dysfunction [47]. We therefore evaluated myocar-
dial function in LV papillary muscle preparations. Dia-
betes increased contraction and relaxation time. Under 
low extracellular calcium concentrations, DM had higher 
developed tension than C, which suggests that diabe-
tes increased myocardial sensitivity to calcium. Altera-
tions in contractile and relaxation function have been 
previously reported in rats with streptozotocin-induced 
Table 2 Echocardiographic structural data
Data are expressed as mean ± standard deviation. One-way ANOVA in a factorial 
design 2 × 2 and Tukey’s post hoc test.
C untreated rats, C-R rutin-treated rats, DM untreated diabetic rats, DM-R rutin-
treated diabetic rats, HR heart rate, LVDD and LVSD left ventricular (LV) diastolic 
and systolic diameter, respectively, PWT LV posterior wall thickness, SWT septal 
wall thickness, LA left atrial diameter, LVM LV mass, RWT relative wall thickness, 
BW body weight.
* p < 0.05 vs C; #p < 0.05 vs C-R; § < 0.05 vs DM.
Parameters C (n = 14) C-R (n = 14) DM (n = 16) DM-R 
(n = 16)
HR (bpm) 292 ± 33 293 ± 32 271 ± 57 283 ± 30
LVDD (mm) 8.12 ± 0.42 8.21 ± 0.36 8.30 ± 0.46 8.35 ± 0.51
LVSD (mm) 3.75 ± 0.57 3.91 ± 0.34 4.26 ± 0.36* 3.97 ± 0.50
PWT (mm) 1.53 ± 0.11 1.53 ± 0.10 1.46 ± 0.07 1.34 ± 0.06#
SWT (mm) 1.65 ± 0.05 1.63 ± 0.08 1.48 ± 0.10* 1.40 ± 0.07#§
LA (mm) 5.76 ± 0.64 6.03 ± 0.71 5.73 ± 0.56 5.36 ± 0.53#
LVDD/BW 
(mm/kg)
18.4 ± 1.81 19.2 ± 2.11 29.2 ± 3.07* 24.7 ± 3.26#§
LA/BW (mm/
kg)
13.0 ± 1.59 14.1 ± 2.47 20.1 ± 2.09* 16.0 ± 2.85§
LVM (g) 0.94 ± 0.10 0.95 ± 0.10 0.89 ± 0.12 0.81 ± 0.11#
LVM/BW (g/kg) 2.13 ± 0.25 2.23 ± 0.30 3.12 ± 0.47* 2.38 ± 0.23§
RWT 0.38 ± 0.04 0.38 ± 0.04 0.36 ± 0.02* 0.32 ± 0.02#§
Table 3 Echocardiographic left ventricular functional data
Data are expressed as mean ± standard deviation. One-way ANOVA in a factorial 
design 2 × 2 and Tukey’s post hoc test.
C untreated rats, C-R rutin-treated rats, DM untreated diabetic rats, DM-R rutin-
treated diabetic rats, FS endocardial fractional shortening, PWSV posterior wall 
shortening velocity, E early diastolic mitral inflow velocity, A late diastolic mitral 
inflow velocity, E/A E/A ratio.
* p < 0.05 vs C; #p < 0.05 vs C-R; §p < 0.05 vs DM.
Parameters C (n = 14) C-R (n = 14) DM (n = 16) DM-R 
(n = 16)
FS (%) 54.1 ± 5.2 52.5 ± 2.87 48.7 ± 3.4* 52.6 ± 4.2§
PWSV (mm/s) 44.5 ± 4.6 44.3 ± 3.54 35.5 ± 5.4* 42.7 ± 4.6§
E (cm/s) 74.1 ± 11.7 66.6 ± 10.2 75.1 ± 14.3 79.8 ± 12.2#
A (cm/s) 52.9 ± 11.3 45.5 ± 8.82 48.1 ± 18.1 63.1 ± 21.8#§
E/A 1.43 ± 0.23 1.51 ± 0.31 1.77 ± 0.82 1.36 ± 0.34§
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diabetes [23, 48, 49]. Data on myofibrils sensitivity to cal-
cium are controversial in diabetes [50–53]. Our results 
are in accordance with some experimental studies. Elec-
trophysiological analysis in rats with alloxan-induced dia-
betes showed increased muscle sensitivity to a decrease 
in external calcium [51]. Also skinned fibers from dia-
betic rats showed a slight increase in calcium sensitivity 
[54]. This increased calcium sensitivity may have played 
a role in the slow relaxation time-course characterized 
by increased time from peak tension to 50% relaxation in 
DM. Other factors such as lower myosin ATPase activ-
ity and abnormal myosin isoenzyme distribution may 
have contributed to the increased time to peak of tension 
observed in the DM group [55].
Cardiac parameters in the normoglycemic rats were 
not changed by rutin, except for reduced right ventricle 
weight. In the diabetic rats, rutin prevented LV hyper-
trophy, left atrium dilation, and systolic dysfunction, 
attenuated LV dilation, and decreased relative wall thick-
ness, thus characterizing cardiac changes as LV eccentric 
remodeling with preserved systolic function. Myocardial 
dysfunction was also attenuated by rutin, as time to peak 
tension was lower in DM-R than DM. Under lower extra-
cellular calcium concentrations, DM-R presented devel-
oped tension values between those of C-R and DM and 
did not significantly differ from either group. Therefore, 
rutin attenuated cardiac remodeling and myocardial dys-
function in rats with streptozotocin-induced diabetes.
Several beneficial effects of rutin have been shown 
in different cardiac injury models. In rats fed a high 
carbohydrate and fat diet, rutin attenuated metabolic 
changes and cardiac remodeling [56]. In control and 
diabetic rats, rutin had a cardioprotective role against 
ischaemia–reperfusion injury [16, 57]. In a clinical set-
ting, this flavonoid decreased systemic blood pressure 
in diabetic patients [40]. The beneficial effects of flavo-
noids have been associated with different mechanisms 
including antiinflammatory, antiallergic, antiviral, and 
anticarcinogenic properties [15]. However, one of their 
most important actions is the anti-oxidant effect [15, 
58]. Flavonoids stabilize reactive oxygen species by react-
ing with the reactive compound of the radical. Rutin can 
inhibit activity of xanthine oxidase, interfere with induc-
ible nitric-oxide synthase activity, inhibit lipoperoxida-
tion and advanced glycation end product generation, and 
protect against mitochondrial damage and iron chelation 
[15, 42, 59–61]. In neonatal rat heart myocyte culture, 
rutin also increased superoxide dismutase activity [57]. 
Several studies have shown the anti-oxidant potential 
of flavonoids in diabetes and other diseases [19, 42, 62]. 
In control and diabetic rats, rutin attenuated oxidative 
stress and increased antioxidant reserves during ischae-
mia–reperfusion injury [16, 57]. As oxidative stress plays 
Table 4 Isolated papillary muscle data at 2.50 mM extracellular Ca2+ concentration
Data are expressed as mean ± standard deviation. One-way ANOVA in a factorial design 2 × 2 and Tukey’s post hoc test.
C untreated rats, C-R rutin-treated rats, DM untreated diabetic rats, DM-R rutin-treated diabetic rats, DT peak of developed tension, TPT time to peak of tension, RT1/2 
time from peak tension to 50% relaxation, +dT/dt maximum rate of tension development, −dT/dt maximum rate of tension decline, CSA papillary muscle cross-
sectional area.
* p < 0.05 vs C; #p < 0.05 vs C-R; §p < 0.05 vs DM.
Parameters C (n = 10) C-R (n = 13) DM (n = 13) DM-R (n = 12)
DT (g/mm2) 5.83 ± 0.86 6.57 ± 2.02 7.00 ± 0.85 6.49 ± 0.66
TPT (ms) 148.23 ± 7.45 146.92 ± 8.07 195.12 ± 8.07* 168.33 ± 14.39#§
RT1/2 159.86 ± 29.59 169.76 ± 14.17 224.62 ± 5.27* 213.43 ± 26.45#
+dT/dt (g/mm2/s) 59.54 ± 9.53 72.65 ± 21.22 66.65 ± 7.71 69.07 ± 11.14
−dT/dt (g/mm2/s) 25.53 ± 4.75 26.93 ± 7.02 23.28 ± 4.25 21.98 ± 3.16
CSA 0.961 ± 0.194 0.962 ± 0.294 0.889 ± 0.140 0.951 ± 0.144
Figure 1 Peak of developed tension (DT) under different extracellu-
lar calcium concentrations. C untreated rats, C-R rutin-treated rats, DM 
untreated diabetic rats, DM-R rutin-treated diabetic rats. Values are 
mean and standard error; Anova and Tukey; *p < 0.05 DM vs C.
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an important role in the pathophysiology of diabetic car-
diomyopathy [22, 23], this study allows us to propose the 
hypothesis that rutin attenuated diabetes-induced car-
diac remodeling and dysfunction through its anti-oxidant 
properties. Additional studies are needed to clarify the 
mechanisms of rutin-induced beneficial effects on dia-
betic cardiomyopathy.
In conclusion, rutin attenuates cardiac remodeling and 
left ventricular and myocardial dysfunction caused by 
streptozotocin-induced diabetes mellitus.
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